Investment Analysts’ Updated EPS Estimates for January, 19th (AAPL, AJG, ALNY, AMED, ANGO, ARE, ASND, DEO, HCLP, HUM)
Apple (NASDAQ:AAPL) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Apple is benefiting from steady iPhone sales, spurt in Services segment and a resurgence in Mac and iPad sales. The company is anticipated to benefit from the strong demand of iPhone X in mature markets, which will help it to sustain momentum in the near term. Going ahead, we believe foray into fast-growing technologies like autonomous vehicle, artificial intelligence (AI) & AR/VR are long-term drivers. Moreover, Apple’s new investment plan will boost its subscription-based services business and put an end to the criticism it is facing for not creating enough jobs in the United States. The company has positive record of earnings surprises in recent quarters.”
Arthur J Gallagher & Co (NYSE:AJG) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Shares of Arthur J. Gallagher have outperformed the industry, in a year's time. The company has also seen its 2018 estimates move north in the last 60 days. Arthur J. Gallagher’s inorganic story seems impressive with strategic buyouts, with the company intending to pursue smaller tuck-in mergers in 2017. It remains focused on tapping opportunities in the U.K., Australia, New Zealand, Canada and the U.S. The company remains focused on enhancing productivity and quality that is a part of its value creation strategy. A solid performance is leading to sufficient cash flows help it deploy capital in shareholder-friendly moves. However, escalating expenses and weak commercial P&C rates pose concerns. Adverse foreign exchange also will weigh on results. It is set to release fourth quarter results on Jan 25. A Zacks Rank #3 increases the predictive power of a beat, but combined with the Earnings ESP of -0.45%, makes prediction difficult.”
Amedisys (NASDAQ:AMED) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Over the past year, Amedisys has been trading above the broader industry. The company is currently exploring new opportunities in both Home Health and Hospice. At the Home Health division, the company witnessed a decline in Medicare revenues, while there was an improvement in non-Medicare revenues. At the Hospice division, the company registered strong growth across all segments. A favorable demographic trend and strategic acquisitions bode well for the company. On the flip side, escalating operating expenses and declining gross margin continue to raise concerns. Also, an intense competitive landscape and regulatory concerns continue to pose challenges in the home health and hospice industry.”
AngioDynamics (NASDAQ:ANGO) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Despite trading below the broader industry in the last year, market’s solid response to Solero platform, especially within the Microwave Ablation space, is likely to boost AngioDynamics. The company has been offering a broad spectrum of products which has helped widen its commercial opportunities. AngioDynamics is also a leading player in the thrombolytic catheters space. The company boasts highly unique catheters like Uni-Fuse, SpeedLyser and Pulse Spray under the thrombus portfolio. On the flipside, the company’s Peripheral Vascular business segment witnessed a downside scenario. The company also had a high outstanding debt level at the end of the second quarter. AngioDynamics’ higher debts impose certain operating and financial restrictions which limit the company’s execution of the company’s core business strategies. The company also recalled the Acculis Microwave Tissue Ablation System recently.”
Alexandria Real Estate Equities (NYSE:ARE) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Shares of Alexandria have outperformed the industry in the past six months. Further, the stock has seen the Zacks Consensus Estimate for 2018 funds from operations (FFO) per share being revised upward in a month’s time. The fundamentals of the life science industry remain strong and the company’s solid portfolio, consisting of Class A properties in upscale locations, enjoys strong demand. This enables the company to enjoy high occupancy and generate steady rental revenues from its properties. Moreover, on Jan 8, Alexandria closed the public offering of 6.9 million shares. This adds to its existing capital buffer which will likely cushion its position during any adverse situation. However, sale of non-core assets is anticipated to have a dilutive impact on earnings and rate hike add to its woes.”
Ascendis Pharma A/S (NASDAQ:ASND) had its buy rating reaffirmed by analysts at HC Wainwright.
Diageo (NYSE:DEO) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Shares of Diageo have outperformed the industry in the past one year, driven by its strong fundamentals, continuous innovation and focus on expansion. Also, the company’s strategic endeavors including growth via acquisitions remain noteworthy. In fact, the buyout of the U.S. fastest-growing premium tequila brand, Casamigos, is expected to boost its market share in the category and is likely to capitalize on the company’s presence in the high-growth international markets. Notably, alcohol stocks are doing well backed by the rising demand for flavored whisky, premium tequilas and spirits. Further the company has been striving toward expanding its presence in emerging regions as well as focus on high-margin products. However, currency fluctuations as well as other macroeconomic factors such as interest rate hikes and increase in fuel and energy costs may also impact the company’s profitability.”
Consolidated Edison (NYSE:ED) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Consolidated Edison has a favorable rate decisions history by regulatory authorities, which will likely encourage it to invest more in infrastructure improvements. It continues to follow a systematic capital investment plan for infrastructure development and the expansion of renewable assets. The company is also making notable progress in generating renewable energy. Moreover, the company outperformed the broader industry in past one year. However, the company faces interest rate risk owing to variable rate debt and to new debt financing, needed to fund capital requirements. It also faces commodity price risk related to the purchase and sale of its electricity, gas and related derivative instruments. The management believes that a 10% decline in market prices may result in a decline in fair value of $66 million for the derivative instruments used by the company to hedge purchases of electricity and gas.”
Hi-Crush Partners (NYSE:HCLP) had its buy rating reissued by analysts at B. Riley. They currently have a $16.00 price target on the stock.
Humana (NYSE:HUM) was downgraded by analysts at Zacks Investment Research from a strong-buy rating to a hold rating. According to Zacks, “Humana is well poised to grow on its strong government business. Its top line has been witnessing an uptrend for past many years. Sufficient generation of cash flow has helped the company take up several capital deployment initiatives aimed at enhancing shareholders’ value. Humana’s sound balance sheet and disciplined capital management remain major tailwinds. Following its strong third-quarter 2017 results, the company raised its 2017 earnings guidance. Although its shares have underperformed the industry in a year's time, its strong fundamentals are likely to help the stock gain momentum going forward. However, the company's individual commercial business has remained a drag over past few years. Rising level of expenses also continues to weigh on the bottom line. Humana will release its fourth-quarter and full year 2017 results on Feb 7, 2018 before the market opens.”
International Business Machines (NYSE:IBM) had its hold rating reissued by analysts at Cantor Fitzgerald. They currently have a $152.00 price target on the stock.
Inphi (NYSE:IPHI) had its buy rating reissued by analysts at B. Riley. They currently have a $48.00 target price on the stock.
J.B. Hunt Transport Services (NASDAQ:JBHT) had its buy rating reaffirmed by analysts at Loop Capital. Loop Capital currently has a $145.00 target price on the stock.
Newmont Mining (NYSE:NEM) was downgraded by analysts at Zacks Investment Research from a strong-buy rating to a hold rating. According to Zacks, “Newmont’s shares have outperformed the industry it belongs to in the past six months. The company is making notable progress with its growth projects. We are also impressed with its efforts to reduce debt and improve efficiency. Moreover, the acquisition of CC&V represents a significant opportunity. However, the company is exposed to a highly volatile gold price environment. It also faces headwinds from high production costs. The company's falling gold reserve base is another concern.”
Netflix (NASDAQ:NFLX) had its hold rating reiterated by analysts at B. Riley. The firm currently has a $211.00 target price on the stock.
Playa Hotels & Resorts (NASDAQ:PLYA) had its buy rating reiterated by analysts at Nomura. They currently have a $16.00 price target on the stock.
ResMed (NYSE:RMD) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Over the recent past, ResMed has been observed to achieve strong global revenue growth led by sales from Software-as-a-Service businesses as well as its new mask products and devices. We are encouraged to note that the company is working on product innovation through extensive research and development. The company also recently launched the AirFit N20 Classic nasal mask for positive airway pressure (PAP) treatment in Europe. In the past six months, ResMed has traded above the broader industry. However, challenges like competitive bidding and reimbursement issues continue to plague ResMed. The company also remains exposed to foreign exchange fluctuations. Rising operating expenses and a weak operating margin are other major concerns.”
Starbucks (NASDAQ:SBUX) had its buy rating reaffirmed by analysts at Oppenheimer Holdings Inc.. The firm currently has a $66.00 target price on the stock.
Sierra Metals (NYSEAMERICAN:SMTS) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $4.25 price target on the stock.
Sorrento Therapeutics (NASDAQ:SRNE) had its buy rating reiterated by analysts at Oppenheimer Holdings Inc.. The firm currently has a $9.00 price target on the stock.
Texas Instruments (NASDAQ:TXN) had its buy rating reaffirmed by analysts at Oppenheimer Holdings Inc.. Oppenheimer Holdings Inc. currently has a $130.00 price target on the stock.
Receive News & Ratings for Apple Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apple Inc and related companies with MarketBeat.com's FREE daily email newsletter.